Fibroblasts could serve as new key to enhancing personalized treatment for lung cancer patients
Researchers have identified three functional subtypes of these cells, which correspond to patients’ treatment response.
Contact Information
Boston, MAPhone: 617-726-5130
Newton, MAPhone: 617-219-1230
Video: Meet Dr. Sequist and learn about early detection of cancer
Dr. Sequist is originally from Michigan and studied chemistry at Cornell University. She received her MD from Harvard Medical School and trained in internal medicine at the Brigham and Women’s Hospital and in hematology/oncology at the Dana-Farber Cancer Institute, where she also received an MPH from the Harvard School of Public Health. She joined the faculty at the Mass General Brigham Cancer Institute in 2005 and has an active clinical and translational research career, as well as a busy practice caring for patients with lung cancer. She is currently the Landry Family Professor of Medicine at Harvard Medical School and the Program Director of the Early Detection and Diagnostics Program at Mass General Brigham Cancer Institute. She has held grants from the NIH, the DOD, and many private foundations. Dr. Sequist’s research focuses on studying targeted therapeutics for lung cancer and bringing new non-invasive tests like circulating tumor cells and circulating tumor DNA to treat and detect lung cancer. In her free time, she likes to spend time with her husband, two sons and her dog, and is a hockey and dance mom.
Departments, Centers, & Programs:
Clinical Interests:
Treats:
Mass General Brigham Cancer Institute
55 Fruit St.
Boston, MA 02114
Phone: 617-726-5130
Phone: 877-726-5130
Mass General Brigham Cancer Institute at Newton-Wellesley Hospital
2014 Washington St.
Newton, MA 02462
Phone: 617-219-1230
Medical Education
American Board Certifications
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Secure online access to your health information whenever you need it. Check appointments, communicate with your provider and pay bills online 24/7.
Mass General is recognized as a top hospital on the U.S. News Best Hospitals Honor Roll for 2025-2026.
Researchers have identified three functional subtypes of these cells, which correspond to patients’ treatment response.
Using information from a single low-dose chest computed tomography scan, ‘Sybil’ accurately predicted individuals’ lung cancer risk for one to six years in the future, pointing a way toward personalized screening.
A team of MGH clinicians and other lung cancer advocates stopped by the Boston Fire Department District 3 firehouse on Cambridge Street Nov. 1 to kick off National Lung Cancer Awareness Month.
Clinical trials conducted by researchers at the Massachusetts General Cancer Center show encouraging results for the third generation EGFR inhibitor in treating NSCLC with reduced side effects.
The Mass General Cancer Center's Dr. David Ryan and Dr. Lecia Sequist were named leaders for two of the four teams.
Mass General Cancer Center's Dr. Lecia Sequist sits down with Kiss 108's Billy Costa to discuss the importance of early detection.

Reviews: Comments and Ratings